Arvinas inks over $1.0 billion deal with Novartis

Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN).Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Details of Arvinas – Novartis agreementCopy link to sectionNovartis will pay $150 million to the pharmaceutical company up front. In return, it will secure license (exclusive) for development and commercialisation of its second-gen treatment for prostate cancer or ARV-766. The S ...